Selected Immunicum-related Posters & Publications

Treatment with an Allogeneic Leukemia-derived Dendritic Cell Vaccine in AML patients shows MRD conversion and improved survival

van de Loosdrecht, A.A. et al.

2021 ASH Annual Meeting Poster

CD47 and phosphatidylserine contribute to the interaction between antigen presenting cells and the allogeneic cell-based relapse vaccine DCP-001

Zuo, H. et al.

SITC 2021 Congress Poster

Zuo et al. Transfer of Cellular Content from the Allogeneic Cell-Based Cancer Vaccine DCP-001 to Host Dendritic Cells Hinges on Phosphatidylserine and Is Enhanced by CD47 Blockade. Cells 2021 (link to PubMed)

Preclinical studies support therapeutic application of the leukemic cell-based cancer relapse vaccine DCP-001 in ovarian cancer

Nagasawa, M. et al.

SITC 2020 Virtual Congress Poster

Development of a humanized immunocompetent mouse model to study the relapse vaccine DCP-001

Leitch, C. et al.

EHA 2020 Virtual Meeting Poster

Intratumoral injection of allogeneic pro-inflammatory dendritic cells (ilixadencel) in combination with anti-CTLA-4 treatment induce complete        tumor responses and anti-tumor immune memory in a mouse tumor model

Alex Karlsson-Parra (1, 2), Alexandros Iskantar (1), Di Yu (1) and Chuan Jin (1)

(1) Department of Immunology, Genetics and Pathology, The Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; (2) Immunicum AB, Stockholm, Sweden

ESMO 2020 Virtual Congress

A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma

Magnus Lindskog, MD, PhD; Uppsala University Hospital, Sweden

ASCO-SITC 2020 Podium Presentation

Karlsson-Parra et al. Phase 1 Trial Evaluating Safety And Efficacy Of Intratumorally Administered Allogeneic Monocyte-Derived Cells (ilixadencel) In Advanced Gastrointestinal Stromal Tumors. ASCO-SITS Clinical Immuno-Oncology Symposium 2020

ASCO-SITC 2020 GIST Poster #15

Durable responses and survival in high risk AML and MDS patients treated with an allogeneic leukemia-derived dendritic cell vaccine

Janssen, L.G. et al.

ASH 2019 Poster Presentation

Novel vaccination strategies using tumour-independent antigens to induce anti-tumour immunity in solid tumours.

Sommandas, V., Kaur Singh, S., & Manting, E.H.

SITC 2019 Poster Presentation

Rizell et al. Phase I Trial with the Cell-Based Immune Primer Ilixadencel, Alone and Combined with Sorafenib, in Advanced Hepatocellular Carcinoma. Front Oncol 2019
(link to journal)

Karlsson-Parra et al. Intratumoral administration of pro-inflammatory allogeneic, off-the-shelf, dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect. European Society for Medical Oncology (ESMO) Congress 2018
(link to pdf)

Karlsson-Parra et al. Ilixadencel – an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration. Pharm Res 2018 (link to PubMed)

Rizell et al. Combination treatment of immune primer ilixadencel with standard therapy known to inhibit immunosuppression: a case report. Cholangiocarcinoma Foundation Annual Conference 2018 (link to pdf)

Fotaki et al. Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models. Oncoimmunology 2017 (link to PubMed)

Fotaki et al. Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses. Oncoimmunology 2017 (link to PubMed)

Fotaki et al. In vitro mode of action of ilixadencel – a cell-based allogeneic immune primer for intratumoral administration. Society for Immunotherapy of Cancer (SITC) Annual Meeting 2018 (link to pdf)

Laurell et al. Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma. J Immunother Cancer 2017 (link to PubMed)